2021
DOI: 10.1016/j.jpba.2020.113777
|View full text |Cite
|
Sign up to set email alerts
|

Recent advances in cardiac biomarkers detection: From commercial devices to emerging technologies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 26 publications
(18 citation statements)
references
References 132 publications
(546 reference statements)
0
12
0
Order By: Relevance
“…35 Microfluidic patterns are directly machined from a cyclic olefin copolymer (COC) sheet (TOPAS, US) using DATRON M7HP equipment. The stretchable membrane is positioned between the fluidic card (1) and the pneumatic card (2). In this new microfluidic cartridge, both fluidic and pneumatic layers contain hemispherical chambers to increase the volumes of interest compared to our previous study.…”
Section: Chip Fabricationmentioning
confidence: 99%
See 1 more Smart Citation
“…35 Microfluidic patterns are directly machined from a cyclic olefin copolymer (COC) sheet (TOPAS, US) using DATRON M7HP equipment. The stretchable membrane is positioned between the fluidic card (1) and the pneumatic card (2). In this new microfluidic cartridge, both fluidic and pneumatic layers contain hemispherical chambers to increase the volumes of interest compared to our previous study.…”
Section: Chip Fabricationmentioning
confidence: 99%
“…For instance, in clinical diagnostics, the detection of cardiac biomarkers such as troponin 1 is of huge interest. 2 A portable device could improve chest pain patients' flow management in the emergency department. 3 Food safety is another broad field of application 1,4,5 where on site testing could provide fast results to isolate immediately a contaminated batch and prevent foodborne illnesses.…”
Section: Introductionmentioning
confidence: 99%
“…Mortality profiles and trends are often presented to healthcare personnel as the basis for critical decisions regarding the public's welfare, now and in the future [8]. Since mortality is considered one constant demographic process, preventing its occurrence has been a motivation for the rapid cardiac health advancements available today [9]. Unfortunately, access to these developments is unequal among different population sectors, causing disparities in cardiac health outcomes.…”
Section: Introductionmentioning
confidence: 99%
“…CVD is a major public health concern and imposes a huge economic burden on people and governments. Cardiac troponin (cTn-I) is the most promising biomarker for CVD, and cTn-I biosensors are employed for the clinical diagnosis of CVD [ 3 ]. As the ranges of cTn-I levels in serum are in the pg/mL level, functional nanomaterials, which enhance the sensitivity and detection ranges of cTn-I biosensors, are needed to increase their performance [ 4 , 5 ].…”
Section: Introductionmentioning
confidence: 99%